Navigation Links
Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
Date:10/18/2010

WORCESTER, Mass., Oct. 18 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT, www.generex.com) announced today that Dr. Joseph Rubinfeld, an independent scientific advisor to the Company and a member of the Company's Scientific Advisory Board, issued the following statement in respect of the reverse stock split proposal being considered at today's special meeting of the Generex stockholders:

"Having been intimately involved in the drug development world for over 40 years, I have hands-on experience with the dilemma faced by Generex and its shareholders on the day of this important vote.  Many shareholders have personal experience with a reverse split or a delisting which has helped to shape their opinion on how to vote. Still others may look to point the finger of blame at management regardless of the current management's role in arriving at this point. I believe that it is important for every shareholder at this time to carefully consider the future in casting their vote as opposed to looking in the rear view mirror.  I myself am confident that Generex has the ability to become a powerful force in immunotherapeutic vaccines and delivery of metabolic drug therapies but, there is still work ahead.  That work includes further clinical trials and, in time, collaboration with larger pharmaceutical companies.  As we continue to do this work we will look to the capital markets and there is no doubt that our financing opportunities will be more advantageous to our current shareholder base as a NASDAQ listed company.  The same holds true when negotiating with potential partners. Generex stock is at a crossroads and I believe that approving the reverse split proposal is at this time in the best interest for the company and its stockholders as in the long term it will place the company on a more solid footing and result in much less overall dilution.  I urge all who have not v
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
7. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
8. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
9. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
10. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
11. China-Biotics, Inc. Provides Update on Construction of New Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... MD (PRWEB) July 28, 2014 ... personalized medicine, will be exhibiting data and research conducted ... International Spine Intervention Society’s (ISIS) 22nd Annual ... 3rd, at the Hyatt Regency, in Orlando, Florida. ... knowledge and clinical competence of physicians who care for ...
(Date:7/28/2014)... DALLAS , July 28, 2014 /PRNewswire/ ... research report  "Microbial Identification Market by Products (Consumables, Instruments, ... & Beverages), End User (Detection, Characterization) - ... global Microbial Identification Market is estimated at ... to reach $1,194.1 Million by 2019, growing ...
(Date:7/28/2014)... --  Propeller Health , the FDA-cleared digital health solution ... Brad Towle as Senior Vice President, Business and ... company,s sales growth, customer acquisition and program expansion. ... past role in the development of accountable care organizations, ... time in the industry," said David Van Sickle ...
(Date:7/28/2014)... 28, 2014 The global market for ... 2020, according to a new study by Grand View ... demand for effective vaccines and drugs in an attempt ... needs is expected to drive market demand over the ... agricultural productivity via the use of genetically engineered seeds ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4
... 12 VIA Pharmaceuticals,Inc. (Nasdaq: VIAP ), a ... treatment of cardiovascular disease, announced today that,James G. Stewart, ... present a company update at the Fourth Annual Noble ... 19, 2008 at the Loews Lake,Las Vegas Resort in ...
... and Webcast on Monday, August 18, 2008, ... Beginning at 1:00 PM Eastern Time, LIVINGSTON, ... recognized leader in,advanced injection technologies, today announced that it plans to ... 2008 on the morning,of Thursday, August 14, 2008., Milestone Scientific ...
... DSM Biologics and MorphoSys,AG (Frankfurt Stock Exchange: ... signing of a Biopharmaceutical Manufacturing Agreement,covering process ... is a,fully human HuCAL(R) antibody, directed against ... multiple myeloma. DSM Biologics will manufacture,MOR202 in ...
Cached Biology Technology:VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference 2Milestone to Report Results for 2008 Second Quarter on Thursday, August 14, 2008 2DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody 2DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody 3
(Date:7/28/2014)... Rice University researchers are using magnetic beads and ... can be used as microscale models for polymer macromolecules. ... introduced as theory in the 1950s, can be made ... be of interest to materials scientists who study the ... Rice chemical and biomolecular engineer Sibani Lisa Biswal and ...
(Date:7/28/2014)... killers to prevent and treat HIV infection has been ... these molecules can arouse as they get rid of ... the Weizmann Institute and the National Institutes of Health ... molecules interferons around the time of infection ... disease. Their research appeared in Nature . ...
(Date:7/28/2014)... explorer Roald Amundsen became the first man to reach ... 100 years later, an international team of scientists led ... have proven that air pollution from industrial activities arrived ... collected from widely spaced locations around the Antarctic continent, ... accurate and precise reconstruction to date of lead pollution ...
Breaking Biology News(10 mins):Seeing is bead-lieving 2Interfering with interferon 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3
... are losing about 1.6 million tonnes of carbon per year ... economy and carbon accounts, according to new research.,Top soil is ... away by events such as the ,Red Dawn, in Sydney ... the atmosphere it changes the amount and location of soil ...
... Improved diagnosis for people afflicted with carpal tunnel syndrome ... is the goal of a research collaboration led by an ... Clinic physician. Marco Santello and Mark Ross were recently ... Medicine to advance their effort to quantify the effects of ...
... help determine the vulnerability of public-supply wells to contamination. ... into which contaminants in an aquifer might reach a ... might arrive. About one-third of the U.S. population ... the understanding of the vulnerability of public-supply wells to ...
Cached Biology News:Soil carbon 'blowing in the wind' 2ASU-Mayo research project targets carpal tunnel syndrome diagnosis 2New insight on vulnerability of public-supply wells to contamination 2
Modified and insect cell culture tested....
Bethyl Laboratories Epitope Retrieval Buffer-Reduced pH will unmask antigenic sites from formaldehyde fixation and allow for subsequent immunostaining. Shelf-Life: 1 year from date of receipt...
Mycoplasma and virus tested...
Edited by Benjamin Lewin (1997) • This book gives an integrated account of the structure and function of genes in both prokaryotic organisms and is thoroughly up to date with the latest thinking...
Biology Products: